Arialys Therapeutics Raises $58M For Autoimmune Disease Treatment
Arialys Therapeutics has secured $58 million in seed funding for the development of treatments targeting autoimmune neuropsychiatric diseases. Arialys Therapeutics,…
Arialys Therapeutics has secured $58 million in seed funding for the development of treatments targeting autoimmune neuropsychiatric diseases. Arialys Therapeutics,…
Depression is a starting point for schizophrenia. After a long period of depression, it leads to schizophrenia, which can be…